Abstract
Objective: To assess the efficacy of inhaled, repeat doses (28 days) of the glucocorticoid agonist GW870086.
Methods: This was a randomised, placebo-controlled, parallel group study in subjects with persistent asthma (n=135) who received GW870086 (2, 3, or 4 mg, once-daily) or placebo.
Results: Improvements in forced expiratory volume in one second (FEV1) were seen following all three doses of GW870086 relative to placebo. Mean improvements (95% confidence interval) of: 0.172 L (0.015, 0.329), 0.105 L (-0.053, 0.263) and 0.159 L (0.001, 0.316) were observed for 2 mg, 3 mg and 4 mg, respectively, at Day 28. Peak expiratory flow rate results were consistent with FEV1 and rescue medication was administered more frequently in the placebo group than all three GW870086 treatment arms.
Conclusion: This study provided a positive outcome with all doses of GW870086 demonstrating improvements in lung function compared with placebo.
Keywords: Diskhaler, glucocorticoid, inhaled corticosteroid, repeat dose.
Current Drug Therapy
Title:Efficacy of a New Selective Steroid (GW870086) in Asthma: An Adaptive, Randomised, Controlled Trial
Volume: 8 Issue: 2
Author(s): Philippe Bareille, Kelly Hardes, Jonathan Robertson, Angela Davis and Ann Allen
Affiliation:
Keywords: Diskhaler, glucocorticoid, inhaled corticosteroid, repeat dose.
Abstract: Objective: To assess the efficacy of inhaled, repeat doses (28 days) of the glucocorticoid agonist GW870086.
Methods: This was a randomised, placebo-controlled, parallel group study in subjects with persistent asthma (n=135) who received GW870086 (2, 3, or 4 mg, once-daily) or placebo.
Results: Improvements in forced expiratory volume in one second (FEV1) were seen following all three doses of GW870086 relative to placebo. Mean improvements (95% confidence interval) of: 0.172 L (0.015, 0.329), 0.105 L (-0.053, 0.263) and 0.159 L (0.001, 0.316) were observed for 2 mg, 3 mg and 4 mg, respectively, at Day 28. Peak expiratory flow rate results were consistent with FEV1 and rescue medication was administered more frequently in the placebo group than all three GW870086 treatment arms.
Conclusion: This study provided a positive outcome with all doses of GW870086 demonstrating improvements in lung function compared with placebo.
Export Options
About this article
Cite this article as:
Bareille Philippe, Hardes Kelly, Robertson Jonathan, Davis Angela and Allen Ann, Efficacy of a New Selective Steroid (GW870086) in Asthma: An Adaptive, Randomised, Controlled Trial, Current Drug Therapy 2013; 8 (2) . https://dx.doi.org/10.2174/1574885511308020001
DOI https://dx.doi.org/10.2174/1574885511308020001 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Possible Role for Interleukin 37 in the Pathogenesis of Behcet's Disease
Current Molecular Medicine The Innate Immune System and Fever under Redox Control: A Narrative Review
Current Medicinal Chemistry Treatment with Paracetamol is not Associated with Increased Airway Sensitivity and Risk of Asthma in Rats
Current Drug Safety Epinephrine and its Role in the Development of Obesity and Hypertension
Current Hypertension Reviews Structure and Function in COPD
Current Respiratory Medicine Reviews Microglial Activation as a Compelling Target for Treating Acute Traumatic Brain Injury
Current Medicinal Chemistry Anti-inflammatory Potential of GSK-3 Inhibitors
Current Drug Targets The Clinical Pathway for Hypertensive Patient of Local Health Unit, Hospitals and General Practitioners, the Milan Experience
Reviews on Recent Clinical Trials A Sensitive Microscale HPLC-UV Method for the Determination of Doxofylline and its Metabolites in Plasma: An Adapted Method for Therapeutic Drug Monitoring in Children
Current Pharmaceutical Analysis T Lymphocytes as Targets of Statins: Molecular Mechanisms and Therapeutic Perspectives
Inflammation & Allergy - Drug Targets (Discontinued) Fibromyalgia and Bipolar Disorder: Emerging Epidemiological Associations and Shared Pathophysiology
Current Molecular Medicine Solid Phase Extraction Method for the Determination of Cobalt in Water Samples on Duolite XAD-761 Resin Using 4-(2-Pyridylazo) Resorcinol by FAAS
Current Analytical Chemistry The Pharmacogenetics of Asthma Therapy
Current Drug Targets Decreased Parathyroid Hormone Levels Despite Persistent Hypocalcemia in Patients with Kidney Failure Recovering from Septic Shock
Endocrine, Metabolic & Immune Disorders - Drug Targets Maternal Vitamin D Status and Development of Asthma and Allergy in Early Childhood
Mini-Reviews in Medicinal Chemistry Modifying Toll-like Receptor 9 Signaling for Therapeutic Use
Mini-Reviews in Medicinal Chemistry Insights into Oxidative Stress: The Isoprostanes
Current Medicinal Chemistry Endogenous Repair System of Oxidative Damage of DNA
Current Chemical Biology Chemistry and Pharmacology of Bioactive Molecule -Coenzyme Q10: A Brief Note
Current Bioactive Compounds Substance P and its Inhibition in Ocular Inflammation
Current Drug Targets